Universal Health Services (UHS) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is constructive — consensus is a manageable bar, the ~$100M Florida Medicaid supplemental payment is a known Q2 tailwind, and management guided to an earnings ramp through the year; the biggest swing factor is how much the ACA exchange payer-mix headwind has steepened relative to the $75M full-year assumption.

UHS heads into Q2 2026 earnings with a well-telegraphed setup: the company reiterated full-year guidance on the Q1 call and has since confirmed at both the BofA (May 12) and Goldman Sachs (June 9) conferences that its core assumptions remain intact. The single largest known positive is the ~$100M incremental Florida fiscal-year 2025 Medicaid supplemental payment that management explicitly flagged for Q2 recording — a material, pre-announced earnings driver that should anchor the beat. On the volume side, management expects both acute and behavioral volumes to improve sequentially from Q1's weather-depressed 1.6% behavioral adjusted patient day growth, supported by 178 new acute beds coming online across three existing-hospital projects in Q2 and moderating behavioral headcount growth (stepping down toward 2%). The ACA exchange headwind is the key wildcard: HCA's July 14 pre-announcement revealed a far worse-than-expected exchange-to-uninsured conversion (nearly 1-for-1, $400M EBITDA impact in Q2), which raises the risk that UHS's $75M full-year exchange assumption is too optimistic — management acknowledged the impact would 'steepen as the year goes on' and that Q2 would provide more clarity. The stock has recovered ~7% over the past month from its lows but remains down ~24% over six months, trading at a deeply discounted ~5.1x NTM EV/EBITDA versus the peer group, suggesting the market has already priced in meaningful downside; any guidance hold or raise would likely be a positive catalyst, while a guidance cut driven by exchange exposure would confirm the bear case.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a moderate bar — the Diluted Operating EPS estimate of ~$5.96 is up from Q1's $5.62 actual, implying the market already expects a sequential ramp; the bigger swing factor is whether the Florida Medicaid supplemental payment and behavioral volume recovery materialize as guided, or whether the ACA exchange headwind forces a guidance cut that overwhelms both.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data (UHS IS, AC, BH segments). Q2 2026 consensus as of July 25, 2026. FY 2026 guidance from Q1 2026 earnings call (April 28, 2026) and BofA/Goldman Sachs conference disclosures.

Table 2 — Beat / Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Diluted EPS — Operating

Pattern: UHS has beaten operating EPS consensus in 6 of the last 7 reported quarters, with an average positive surprise of ~+9% — the one miss (Q4 2025) was narrow at -0.7%. The consistent beat pattern reflects management's conservative guidance posture and the lumpy but additive nature of Medicaid supplemental payment timing.

Source: Visible Alpha Consensus and Actuals Data (UHS IS).

KPI 2: Net Revenues

Pattern: Revenue beats are consistent but modest (averaging ~+1.5% when positive), with two narrow misses in Q1 2025 and Q4 2025. Revenue surprises are smaller than EPS surprises, suggesting the upside is primarily driven by cost management and supplemental payment timing rather than top-line outperformance.

Source: Visible Alpha Consensus and Actuals Data (UHS IS).

3. Guidance & Commentary Evolution

Key Takeaway: Full-year guidance has been reiterated unchanged since the February 25 initial issuance; the only material post-Q1 update is the confirmed ~$100M incremental Florida Medicaid supplemental payment for Q2, which was disclosed in the Q1 10-Q and confirmed at both the BofA and Goldman Sachs conferences — management's tone remains constructive but cautious on the ACA exchange trajectory.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 have been revised modestly higher since the Q1 print (+3.3% for EPS, +0.8% for revenue), reflecting the confirmed Florida supplemental payment; FY 2026 estimates are essentially flat, suggesting the market is treating the supplemental payment as a pull-forward rather than a structural upgrade — the gap between consensus and guidance is narrow, leaving little cushion if the exchange headwind proves worse than modeled.

Commentary: The Q2 EPS estimate revision (+3.3%) is almost entirely attributable to the confirmed $100M Florida supplemental payment, which was not fully in consensus at the time of the Q1 print. FY estimates are essentially flat, consistent with management's guidance reiteration — the market is not yet pricing in either a guidance raise or cut. The key risk is that HCA's Q2 experience (exchange headwind of $400M EBITDA, nearly double its prior assumption) suggests UHS's $75M full-year exchange assumption may be too conservative, which could force a guidance cut at Q2 that would pressure FY estimates.

Source: Visible Alpha Consensus and Actuals Data (UHS IS, AC, BH segments). As-of date May 5, 2026 used as post-Q1 baseline.

5. Stock Performance

Key Takeaway: The ~24% six-month decline is almost entirely multiple compression (EV/EBITDA contracted from ~6.4x to ~5.1x, a -22% move), not estimate cuts — the market has de-rated UHS on regulatory risk (exchange subsidies, Medicaid work requirements, supplemental payment phasedown) even as estimates have held; the stock now trades at a 63% discount to the peer group median, the widest gap in recent history, suggesting sentiment is the primary driver and any guidance hold could catalyze a re-rating.

Relative Valuation vs. Peer Group (NTM EV/EBITDA)

Source: Implied stock performance decomposition data (NTM EV/EBITDA multiples as of July 24, 2026). Peer group: Medical Care Facilities (HCA, THC, DVA, EHC, ENSG, ACHC, and others).

6. Material News & Developments (Since Q1 2026 Earnings, April 28, 2026)

Key Takeaway: The most important development is HCA's July 14 pre-announcement revealing a far worse-than-expected ACA exchange-to-uninsured conversion — a direct and material negative read-through for UHS's $75M full-year exchange assumption; partially offset by THC's July 23 beat-and-raise, which demonstrated that disciplined cost management can overcome exchange headwinds.

• July 23–24, 2026 — Tenet Healthcare (THC) Q2 2026 Beat-and-Raise: THC reported Q2 adjusted EPS of $6.12 vs. consensus of $4.26 (+44% beat) and raised full-year EPS guidance to $20.30–$21.69 from $16.38–$18.68. THC cited strong same-store revenue growth and disciplined expense management. THC also announced a $2B buyback increase. Stock surged ~23%. Implication: Positive read-through for UHS — demonstrates that hospital operators with strong cost discipline can absorb exchange headwinds and still beat; raises the bar for UHS's own cost management narrative.
• July 21, 2026 — UHS Adds $700M Delayed Draw Term Loan (8-K): UHS entered into a Twelfth Amendment to its Credit Agreement, adding a $700M delayed draw tranche A term loan facility available through September 30, 2026, maturing 364 days after funding. Proceeds intended for general corporate purposes including refinancing and Talkspace acquisition funding. Implication: Confirms Talkspace close is imminent (Q3 2026); leverage expected to remain in the low 2x range post-close, within the 2–3x long-term target.
• July 14, 2026 — HCA Healthcare Pre-Announcement and Guidance Cut: HCA pre-announced Q2 revenue of $20.23B (above consensus of $19.43B) but cut full-year EPS guidance to $28.70–$30.50 from $29.10–$31.50, citing a $400M Q2 EBITDA headwind from ACA exchange payer-mix shift. Exchange admissions declined 15% YoY; nearly 1-for-1 conversion to uninsured. Full-year exchange impact revised to $1.0–$1.2B from prior $600M–$900M. HCA stock fell ~9.4%. Implication: Significant negative read-through for UHS — UHS's $75M full-year exchange assumption may be materially understated; management will need to address this directly on the Q2 call.
• June 9, 2026 — Goldman Sachs 47th Annual Global Healthcare Conference: Management confirmed: (1) Talkspace on track to close early Q3; (2) 178 new acute beds added across three existing-hospital projects in Q2; (3) Palm Beach Gardens hospital opened May 2026 (30th hospital); (4) $100M Florida supplemental payment to be recorded in Q2; (5) FY26 Florida program still pending but expected at similar size; (6) AI revenue cycle improvements added ~50 bps to acute revenue per unit in 2025. Implication: Constructive tone; no guidance changes; confirms Q2 supplemental payment tailwind.
• May 12, 2026 — BofA Global Healthcare Conference: Management disclosed Florida FY25 Medicaid supplemental program formally approved (noted in Q1 10-Q); incremental benefit of $100M to be recorded in Q2. Behavioral headcount growth expected to moderate to ~2% for full year. Management stated it would be 'a little more aggressive in Q2 on share buyback.' Implication: Confirms the single largest known Q2 earnings driver; buyback acceleration is a modest EPS tailwind.
• April 30, 2026 — Laurel Ridge Treatment Center Medicare/Medicaid Termination: UHS's Laurel Ridge behavioral health facility in San Antonio, TX had its Medicare and Medicaid provider agreements terminated effective April 30, 2026, following CMS findings of noncompliance. Significant workforce reductions announced. Management expects operating losses and cash flow deficits during recertification period with no assurance of recertification. Implication: Modest financial impact (one facility) but a reputational and regulatory overhang; management will likely be asked about recertification timeline on the Q2 call.
• April 24, 2026 — UHS Expands Credit Facilities by $900M: UHS expanded aggregate credit facility capacity by $900M (revolving credit facility expanded to $1.5B) to provide flexibility for Talkspace and continued capital returns. Implication: Balance sheet positioned for Talkspace close; leverage remains conservative.

7. Peer Commentary — Q2 2026 Current-Quarter Read-Throughs

Key Takeaway: Peer Q2 2026 results present a bifurcated read-through: HCA's guidance cut confirms the ACA exchange headwind is worse than UHS modeled, while THC's beat-and-raise demonstrates that strong cost discipline and Medicaid supplemental payments can more than offset exchange pressure — the net read-through is cautiously positive for UHS if its exchange exposure is more limited than HCA's.

Eligibility filter applied: Only HCA and THC Q2 2026 earnings results and commentary (reported July 14 and July 23–24, 2026, respectively) are included below. These peers report on the same calendar quarter (April–June 2026) as UHS. Prior-quarter peer commentary and non-Q2 conference commentary have been excluded.

7A. HCA Healthcare (HCA) — Q2 2026 Results (Pre-announced July 14; Earnings Call July 24)

HCA reported Q2 2026 revenue of $20.23B (+9% YoY, above consensus of $19.43B) and EPS of $7.62 (above consensus of $7.47), but cut full-year EPS guidance to $28.70–$30.50 from $29.10–$31.50 and full-year EBITDA guidance to $15.4–$16.1B from $15.55–$16.45B. The guidance cut was driven entirely by a worse-than-expected ACA exchange payer-mix shift.

7B. Tenet Healthcare (THC) — Q2 2026 Results (Reported July 23–24, 2026)

THC reported Q2 2026 adjusted EPS of $6.12 vs. consensus of $4.26 (+44% beat) and operating revenue of $5.63B vs. consensus of $5.43B (+3.7% beat). Full-year EPS guidance raised to $20.30–$21.69 from $16.38–$18.68. Hospital segment adjusted EBITDA of $762M (+22% YoY) with 18% EBITDA margins. THC announced a $2B buyback increase.

8. Insider Transaction Activity (Since Q1 2026 Earnings, April 28, 2026)

Key Takeaway: No notable open-market insider buying or selling activity has been identified in the post-Q1 window; the absence of discretionary insider selling ahead of earnings is a mild positive signal, consistent with management's stated view that the current share price is 'fairly compelling.'

Note: Company-level share repurchases (not insider Form 4 transactions) have been active — UHS repurchased 675,000 shares at $127M in Q1 2026 and management guided to more aggressive buyback activity in Q2. These are corporate actions, not insider transactions, and are not reflected in the table above.

9. Key Questions for Management

1. ACA Exchange Headwind Update: HCA revised its full-year exchange EBITDA impact to $1.0–1.2B (from $600M–$900M) and THC saw exchange revenues -17% YoY. UHS's current assumption is $75M pre-tax for the full year. What is UHS's updated estimate of the full-year exchange impact, and how does the Q2 experience compare to the $75M assumption? What percentage of UHS's exchange population has converted to uninsured?
2. Florida Medicaid Supplemental Payment (FY26 Program): The FY25 program ($100M incremental benefit) was recorded in Q2. What is the status of the FY26 Florida program approval, and what is management's current estimate of the size and timing of that benefit? Is it included in the reiterated full-year guidance?
3. Full-Year Guidance Update: Management guided to a 5% core earnings growth ramp through the year. Given the steeper-than-expected exchange headwind (per HCA and THC), is the full-year guidance range still achievable? What are the key offsets — supplemental payments, cost management, volume recovery — that support the guidance hold?
4. Behavioral Volume Recovery: Q1 behavioral adjusted patient day growth was 1.6% (weather-impacted). Did Q2 volumes recover toward the 2–3% target as expected? How is the California staffing regulation (effective June 1) affecting behavioral labor costs and capacity in Q2?
5. Cedar Hill and Palm Beach Gardens Ramp: Cedar Hill entered the same-store group in Q2 and management guided to full-year breakeven. How is Cedar Hill tracking vs. the $50M improvement target? Palm Beach Gardens opened in May — what is the expected operating loss for the year, and how does it compare to the West Henderson ramp experience?
6. Talkspace Acquisition Timing and Integration: The $700M delayed draw term loan was added July 20. Is the Talkspace close still on track for early Q3? What are the first integration priorities, and when does management expect to see the first revenue synergies from the bidirectional referral flow?
7. Laurel Ridge Recertification: What is the current status of the Laurel Ridge recertification process? What is the expected financial impact (operating losses, cash flow deficits) for the remainder of 2026, and is this included in guidance?
8. Share Repurchase Activity in Q2: Management guided to 'more aggressive' buyback in Q2. How many shares were repurchased in Q2, and what is the remaining authorization? Does the Talkspace close change the pace of buyback in H2?
9. AI Revenue Cycle — Behavioral Segment: Management noted the behavioral RCM AI improvement initiative is more of a 2027 tailwind given the EHR implementation is still in progress. What is the current timeline for the behavioral EHR rollout, and what is the expected revenue per adjusted patient day benefit once deployed?
10. Medicaid Work Requirements and 2028 Supplemental Payment Phasedown: Management has been lobbying on the 'one big beautiful bill' provisions. What is the latest read on the likelihood of moderating the 2028 supplemental payment phasedown? How is UHS modeling the Medicaid work requirement impact beginning 2027?